CD-19 Antibody Making Waves at JPM2020
A next generation CD-19 mAb, tafasitamab is all the buzz at #JPM2020! #Incyte acquired tafasitamab from #Morphosys, who had been developing the drug under the code name MOR00208 (see link below). While the pipeline for targeting CD-19 has been overwhelmingly CAR-T, tafasitamab is leading the way for increased investment in CD-19 antibodies! #Kognitic's platform enhances big pharma portfolio strategies by giving access to real-time data of all target landscapes. View the image below to see who is driving the CD-19 antibody pipeline!